Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
CC transcript
Inv. presentation
Credit agrmnt [a]
Acq. announced
Director departure
Appointed director
Employment agrmnt
AMAG PHARMACEUTICALS, INC. (AMAG) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/01/2019 8-K Quarterly results
08/07/2019 8-K Investor presentation, Quarterly results
Docs: "AMAG PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Promoted products achieved sequential and year-over-year revenue and market share growth 2019 financial guidance lowered: exiting Makena intramuscular market and removing milestone revenue Vyleesi on-track for national launch in September Conference call scheduled for 8:00 a.m. ET today",
"Copy of AMAG Pharmaceuticals, Inc.’s presentation slides"
12/13/2018 8-K Investor presentation
Docs: "Agreement and Plan of Merger, by and among AMAG Pharmaceuticals, Inc., Magellan Merger Sub, Inc., Perosphere Pharmaceuticals Inc. and Bryan E. Laulicht, as the representative of the Perosphere Equityholders",
"AMAG PHARMACEUTICALS ENTERS INTO DEFINITIVE MERGER AGREEMENT TO ACQUIRE PEROSPHERE PHARMACEUTICALS",
"[LOGO] This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG's belief that ciraparantag will bolster its pipeline of durable growth assets; AMAG's beliefs regarding the clinical efficacy, safety data and population market of ciraparantag and its anticipated regulatory timeline; AMAG's belief that the acquisition structure mitigates risk and maximizes corporate flexibility; the timing and value of future milestone payments; expectations regarding the impact of the transaction on AMAG's preliminary view of its 2019 adjusted EBITDA; expectations regarding the U.S. and world-wide marke..."
06/29/2015 8-K Investor presentation, Credit agreement amendment
Docs: "Stock Purchase Agreement, by and among CBR Holdco, LLC, CBR Acquisition Holdings Corp. and AMAG Pharmaceuticals, Inc",
"AMAG PHARMACEUTICALS TO ACQUIRE CORD BLOOD REGISTRY",
"Investor Presentation by AMAG Pharmaceuticals, Inc., dated June 29, 2015.*"
09/29/2014 8-K Investor presentation
Docs: "Agreement and Plan of Merger, by and among Lumara Health Inc., AMAG Pharmaceuticals, Inc., Snowbird, Inc., and Lunar Representative, LLC as the Stockholders' Representative",
"NOL Amendment, to Shareholder Rights Plan",
"Commitment Letter, by and between AMAG Pharmaceuticals, Inc. and Jefferies Finance LLC",
"AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business",
"Investor Presentation by AMAG Pharmaceuticals, Inc., dated September 29, 2014.*"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy